查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1594981

报导基因分析的全球市场

Reporter Gene Assays
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 88 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球报导基因分析市场将达到 99 亿美元

报导基因分析的全球市场预计 2023 年为 63 亿美元，预计到 2030 年将达到 99 亿美元，在 2023-2030 年分析期间复合年增长率为 6.7%。萤光素酶检测是本报告分析的细分市场之一，复合年增长率为 7.6%，预计到分析期结束时将达到 41 亿美元。在分析期间，萤光蛋白相关检测领域的复合年增长率预计为 7.0%。

美国市场预计19亿美元，中国预计复合年增长率6.2%

预计 2023 年美国报导基因分析市场规模将达 19 亿美元。中国作为世界第二大经济体，预计2030年市场规模将达17亿美元，2023-2030年分析期间复合年增长率为6.2%。其他值得注意的区域市场包括日本和加拿大，在分析期间预计复合年增长率分别为 6.1% 和 5.4%。在欧洲，德国预计复合年增长率为 5.0%。

全球报导基因分析市场—主要趋势和驱动因素总结

报导基因分析在现代研究中扮演什么角色？

报导基因分析在生物医学研究、遗传学和药物开发领域至关重要，是监测基因表现和细胞事件的重要工具。在这些测定中，产生易于测量的蛋白质的「报告」基因被插入目标细胞中。当目标基因或启动子被活化时，报导基因也会表达其蛋白质，从而实现基因活性的可视化和量化。该技术为研究人员提供了关于细胞路径、基因表现动态和各种疾病机制的宝贵见解。对报导基因分析的需求正在显着增长，因为它们提供了一种可靠、高效和非侵入性的观察细胞行为的方法，使科学家能够更好地即时了解细胞反应。鑑于分子生物学和遗传学研究的激增，报导基因分析正在成为研究的重要组成部分，特别是在癌症生物学、神经生物学和免疫学等应用中。

此外，报导基因分析在药物发现中也很重要，用于评估潜在化合物的功效和毒性。製药公司严重依赖这些检测方法，透过监测候选药物与特定细胞路径的相互作用来识别有前途的候选药物。例如，报告基因检测可以测量特定受体的激活，例如 G 蛋白偶联受体 (GPCR)。报导基因分析可在细胞层面上即时洞察药物活性，使研究人员能够在开发过程的早期识别副作用，从而节省时间和资源。这样，报导基因分析就发挥了促进基础研究和加强药物发现管道的双重作用，使其成为各个科学领域的宝贵工具。

科技进步如何影响报导基因分析？

技术进步显着提高了报导基因分析的效率、灵敏度和适用性。例如，生物发光和萤光成像等成像技术的创新使得报导基因活性的可视化变得更加精确。生物发光检测与基因表现表现结合发光，由于其高灵敏度和低背景噪音而越来越受欢迎，可以更准确地测量基因表现。同样，绿色萤光蛋白（GFP）等萤光报导基因由于能够产生可在显微镜下观察到的生动视觉输出而被广泛采用。成像技术的这些进步彻底改变了报导基因分析的基因表现。

此外，高通量筛检技术的发展使研究人员能够利用报导基因分析进行大规模研究，特别是在药物发现方面。高通量系统能够快速测试数千种化合物，并有效评估它们对特定基因和途径的影响。自动化系统和资料分析使研究人员能够快速识别潜在的候选药物并加速药物发现过程。此外，CRISPR-Cas9技术与报导基因分析的结合进一步扩大了其应用范围。基于 CRISPR 的编辑可以精确操作特定基因，而报告基因分析可以让研究人员直接观察这些基因修饰的效果。随着技术的进步，报导基因分析将变得更加通用、适应性更强，并且对生命科学研究和开发至关重要。

报导基因分析面临哪些挑战和机会？

儘管报导基因分析在研究中发挥重要作用，但它也存在一定的限制和挑战。一项主要挑战是来自细胞成分的潜在干扰或“背景噪音”，这有时会影响测定结果的准确性。内源性细胞因子，例如天然存在的酵素和蛋白质，可以与报告基因反应，产生假阳性或阴性结果，从而掩盖真实结果。这个问题在涉及复杂细胞类型或多基因相互作用的测定中尤其严重，因为细胞异质性会使讯号解释变得复杂。另一个挑战是需要专门的设备和技术专业知识来进行和解释研究，这需要资源，并对小型实验室和研究机构构成障碍。

然而，这些挑战正在为报导基因分析市场的创新创造机会。例如，对具有更高特异性和灵敏度的检测的需求不断增长，这推动了新型报导基因和优化检测格式的开发。分裂萤光素酶和分裂 GFP 系统等创新旨在透过分离仅在发生特定细胞间相互作用时发出讯号的报告蛋白来减少背景杂讯并提高测定精度。此外，随着越来越多的製药公司和学术研究机构认识到报导基因分析的价值，提供专业检测服务的委外研发机构(CRO) 的市场也在不断扩大。这些 CRO 提供进行报导基因分析的专业知识和设备，使研究机构能够克服技术和财务限制。透过采用创新解决方案来应对这些挑战，报导基因分析市场有望持续发展和发展，以满足现代科学研究的需求。

加速报导基因分析市场的关键驱动因素是什么？

报导基因分析市场的成长是由反映科学研究和生物技术进步的几个因素所推动的。癌症、神经退化性疾病和感染疾病等疾病的日益流行，推动了对精确分子工具的需求，以帮助阐明疾病机制。报导基因分析为研究疾病途径和製定治疗策略提供了一种有价值的方法，特别是在肿瘤学和免疫学领域，了解基因调控对于有效治疗至关重要。此外，基因研究的增加和 CRISPR 基因编辑技术的采用正在加速需求。研究人员经常使用报导基因分析来评估特定基因修饰对细胞功能的影响。能够即时观察 CRISPR 编辑引起的基因表现变化的报告基因检测对于此类前沿研究至关重要。

另一个关键驱动因素是製药公司和学术研究机构对药物发现研发的投资增加。随着製药业加大对标靶治疗和精准医疗的投资，对报导基因分析等可靠、高效的检测方法的需求正在迅速增加。高通量筛检能力使报告基因检测更具可扩展性，使研究人员能够快速筛检大型化合物库。此外，在研究中越来越多地使用 3D 细胞培养和类器官模型，增加了对报导基因分析的需求，这些检测可以在复杂的生物系统中有效地发挥作用，并产生更多的生理相关结果。最后，政府对生命科学研究的支持政策和资助，特别是在美国和欧洲，正在进一步提振市场。这些驱动因素共同推动了报导基因分析市场的发展，并确保其在生物医学和药物研究中的持续重要性。

部分

类型（萤光素酶测定、萤光蛋白相关测定、氯霉素乙酰转移酶测定、β-半乳糖苷酶测定、β-葡萄醣醛酸酶测定、其他类型）、应用（临床、体外研究）、最终用途（製药/生技）公司、CRO、学术/研究机构、医院/诊断实验室）

调查企业举例（共32家）

  • Abcam PLC
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories
  • Biotium
  • Danaher Corporation
  • Genecopoeia, Inc.
  • Geno Technology, Inc.
  • Invivogen
  • Merck KGaA
  • Perkinelmer
  • Promega Corporation
  • Promocell
  • Thermo Fisher Scientific, Inc.

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他领域

第四章 比赛

简介目录
Product Code: MCP22700

Global Reporter Gene Assays Market to Reach US$9.9 Billion by 2030

The global market for Reporter Gene Assays estimated at US$6.3 Billion in the year 2023, is expected to reach US$9.9 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2023-2030. Luciferase Assays, one of the segments analyzed in the report, is expected to record a 7.6% CAGR and reach US$4.1 Billion by the end of the analysis period. Growth in the Fluorescent Protein-Related Assays segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.9 Billion While China is Forecast to Grow at 6.2% CAGR

The Reporter Gene Assays market in the U.S. is estimated at US$1.9 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 6.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.1% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Reporter Gene Assay Market - Key Trends & Drivers Summarized

What Role Do Reporter Gene Assays Play in Modern Research?

Reporter gene assays are pivotal in the fields of biomedical research, genetics, and drug development, serving as essential tools for monitoring gene expression and cellular events. In these assays, a "reporter" gene, which produces an easily measurable protein, is inserted into a target cell. When the target gene or promoter is activated, the reporter gene also expresses its protein, making it possible to visualize or quantify gene activity. This technique provides researchers with valuable insights into cellular pathways, gene expression dynamics, and the mechanisms of various diseases. The demand for reporter gene assays has grown significantly as they provide a reliable, efficient, and non-invasive means to observe cellular behavior, allowing scientists to better understand cellular responses in real time. Given the surge in molecular biology and genetic research, reporter gene assays are becoming an indispensable component of research, particularly in applications such as cancer biology, neurobiology, and immunology.

Moreover, reporter gene assays are critical in drug discovery, where they are used to evaluate the efficacy and toxicity of potential drug compounds. Pharmaceutical companies rely heavily on these assays to identify promising drug candidates by monitoring their interactions with specific cellular pathways. For instance, reporter assays can measure the activation of certain receptors, such as G-protein coupled receptors (GPCRs), which are often targeted in drug development. By providing real-time insights into drug activity at a cellular level, reporter gene assays enable researchers to identify adverse effects early in the development process, saving time and resources. This dual role of reporter gene assays—advancing fundamental research and enhancing drug discovery pipelines—has positioned them as an invaluable tool across a range of scientific disciplines.

How Are Technological Advancements Shaping Reporter Gene Assays?

Technological advancements are significantly enhancing the efficiency, sensitivity, and applicability of reporter gene assays. For example, innovations in imaging techniques, such as bioluminescence and fluorescence imaging, have enabled more precise visualization of reporter gene activity. Bioluminescent assays, which produce light upon gene expression, have gained popularity for their high sensitivity and low background noise, allowing for more accurate measurements of gene expression. Similarly, fluorescent reporter genes, such as green fluorescent protein (GFP), have been widely adopted due to their ability to produce vivid visual outputs that can be observed under a microscope. These advancements in imaging technology have transformed how researchers utilize reporter gene assays, enabling them to detect and quantify gene expression more effectively and in real time.

Additionally, developments in high-throughput screening technology have allowed researchers to conduct large-scale studies using reporter gene assays, particularly in drug discovery. High-throughput systems enable rapid testing of thousands of compounds, making it possible to assess their effects on specific genes or pathways efficiently. With automated systems and data analytics, researchers can quickly identify potential drug candidates, accelerating the discovery process. Moreover, the integration of CRISPR-Cas9 technology with reporter gene assays has further expanded their applications. CRISPR-based editing allows for precise manipulation of specific genes, and by using reporter assays, researchers can directly observe the effects of these genetic modifications. As technology advances, reporter gene assays are likely to become even more versatile, adaptable, and integral to research and development in life sciences.

What Challenges and Opportunities Lie Ahead for Reporter Gene Assays?

Despite their critical role in research, reporter gene assays face certain limitations and challenges. One major challenge is the potential for interference or “background noise” from cellular components, which can sometimes affect the accuracy of assay results. Endogenous cellular factors, such as naturally occurring enzymes or proteins, may react with the reporter, creating false positives or negatives that obscure the true results. This problem is particularly pronounced in assays involving complex cell types or multi-gene interactions, as cellular heterogeneity can complicate signal interpretation. Another challenge is the need for specialized equipment and technical expertise to conduct and interpret reporter gene assays, which can be resource-intensive and may pose a barrier for smaller research labs or institutions.

However, these challenges also bring opportunities for innovation within the reporter gene assay market. For instance, there is growing demand for assays with higher specificity and sensitivity, which has driven the development of novel reporter genes and optimized assay formats. Innovations such as split-luciferase and split-GFP systems aim to reduce background noise and increase assay accuracy by separating reporter proteins that only emit a signal when specific cellular interactions occur. Additionally, as more pharmaceutical companies and academic research institutions recognize the value of reporter gene assays, the market for contract research organizations (CROs) offering specialized assay services is expanding. These CROs provide expertise and equipment for conducting reporter gene assays, allowing institutions to overcome technical and financial limitations. By addressing these challenges with innovative solutions, the reporter gene assay market is poised to grow and evolve, meeting the needs of modern scientific research.

What Are the Key Drivers Accelerating the Reporter Gene Assay Market?

The growth in the reporter gene assay market is driven by several factors that reflect advancements in scientific research and biotechnology. The increasing prevalence of diseases such as cancer, neurodegenerative disorders, and infectious diseases has fueled the demand for precise molecular tools that can help decode disease mechanisms. Reporter gene assays provide an invaluable method for studying disease pathways and developing therapeutic strategies, particularly in oncology and immunology, where understanding gene regulation is crucial for effective treatment. Furthermore, the rise in genetic research and the adoption of CRISPR gene editing technology have accelerated demand, as researchers frequently use reporter gene assays to assess the impact of specific genetic modifications on cellular functions. The ability to observe real-time changes in gene expression due to CRISPR edits has made reporter assays indispensable in these advanced studies.

Another key driver is the expanding investment in drug discovery and development by both pharmaceutical companies and academic research institutions. As the pharmaceutical industry invests more in targeted therapies and precision medicine, the demand for reliable and efficient testing methods like reporter gene assays has surged. High-throughput screening capabilities have made reporter assays more scalable, allowing researchers to screen large compound libraries quickly. Additionally, the increased use of 3D cell cultures and organoid models in research has led to a growing need for reporter gene assays that can work effectively in complex biological systems, enabling more physiologically relevant results. Finally, supportive government policies and funding for life sciences research, particularly in the United States and Europe, have further boosted the market. Together, these drivers are propelling the reporter gene assay market forward, ensuring its ongoing importance in biomedical and pharmaceutical research.

SCOPE OF STUDY:

The report analyzes the Reporter Gene Assays market in terms of US$ Million by the following Application; End-Use; Type, and Geographic Regions/Countries:

Segments:

Type (Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays, Other Types); Application (Clinical, In-Vitro Studies); End-Use (Pharma & Biotech Companies, Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

  • Abcam PLC
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories
  • Biotium
  • Danaher Corporation
  • Genecopoeia, Inc.
  • Geno Technology, Inc.
  • Invivogen
  • Merck KGaA
  • Perkinelmer
  • Promega Corporation
  • Promocell
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Reporter Gene Assays - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Demand for High-throughput Screening Drives Adoption of Advanced Reporter Gene Assay Technologies
    • Growing Emphasis on Precision Medicine Strengthens Demand for Reporter Gene Assays in Drug Development
    • Rise in Gene Therapy Research Expands Addressable Market for Reporter Gene Assay Applications
    • Advancements in CRISPR and Gene Editing Technologies Propel Growth of Reporter Gene Assays for Target Validation
    • Increasing Focus on Cancer Research Spurs Demand for Reporter Gene Assays in Oncology Studies
    • Expansion of Cell-based Assays for Drug Discovery Drives Adoption of Reporter Gene Assay Tools
    • Growing Integration of Reporter Gene Assays in High-content Screening Expands Opportunities in Complex Studies
    • Technological Innovations in Bioluminescent and Fluorescent Reporters Enhance Sensitivity and Market Demand
    • Adoption of 3D Cell Culture Systems and Organoids Drives Demand for Compatible Reporter Gene Assay Solutions
    • Increasing Need for Real-time Gene Expression Monitoring in Research Boosts Market for Dynamic Reporter Assays
    • Rising Investments in Biotechnology and Pharmaceutical R&D Spur Growth in the Reporter Gene Assay Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Reporter Gene Assays Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Reporter Gene Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World 7-Year Perspective for Reporter Gene Assays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Luciferase Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for Luciferase Assays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Fluorescent Protein-Related Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for Fluorescent Protein-Related Assays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chloramphenicol Acetyltransferase Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Chloramphenicol Acetyltransferase Assays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Beta-Galactosidase Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World 7-Year Perspective for Beta-Galactosidase Assays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Beta-Glucuronidase Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 13: World 7-Year Perspective for Beta-Glucuronidase Assays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Clinical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Clinical by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for In-Vitro Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 19: World 7-Year Perspective for In-Vitro Studies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World 7-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Contract Research Organizations (CROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World 7-Year Perspective for Contract Research Organizations (CROs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 25: World 7-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospital & Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World 7-Year Perspective for Hospital & Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Reporter Gene Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 28: USA Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 29: USA 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 31: USA 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • CANADA
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Canada 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 37: Canada 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • JAPAN
    • Reporter Gene Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 41: Japan 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 43: Japan 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • CHINA
    • Reporter Gene Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 46: China Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 47: China 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 49: China 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • EUROPE
    • Reporter Gene Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Reporter Gene Assays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 53: Europe 7-Year Perspective for Reporter Gene Assays by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 55: Europe 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 59: Europe 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • FRANCE
    • Reporter Gene Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 60: France Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 61: France 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 64: France Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 65: France 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • GERMANY
    • Reporter Gene Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Germany 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 70: Germany Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 71: Germany 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • ITALY
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 73: Italy 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 76: Italy Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 77: Italy 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • UNITED KINGDOM
    • Reporter Gene Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 78: UK Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 79: UK 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 82: UK Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 83: UK 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 89: Rest of Europe 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Reporter Gene Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 95: Asia-Pacific 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 97: Rest of World 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of World 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 100: Rest of World Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 101: Rest of World 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030

IV. COMPETITION